Akebia Therapeutics (STU:AX9) Total Assets: €313.6 Mil (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
50 GF Score
Price €0.98
GF Value €1.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics Total Assets?

Akebia Therapeutics STU:AX9 -0.35% 50 Total Assets is €313.6 Mil as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 50/100 and a GF Value™ of €1.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Akebia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was €313.6 Mil.

During the past 12 months, Akebia Therapeutics's average Total Assets Growth Rate was 1.60% per year. During the past 3 years, the average Total Assets Growth Rate was -10.30% per year. During the past 5 years, the average Total Assets Growth Rate was -16.00% per year. During the past 10 years, the average Total Assets Growth Rate was 27.30% per year.

During the past 13 years, Akebia Therapeutics's highest 3-Year average Total Assets Growth Rate was 431.90%. The lowest was -24.80%. And the median was 95.20%.

Total Assets is connected with ROA %. Akebia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -9.86%. Total Assets is also linked to Revenue through Asset Turnover. Akebia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.15.

Akebia Therapeutics  (STU:AX9) Total Assets Explanation

Total Assets is connected with ROA %.

Akebia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-31.328/( (321.587+313.58)/ 2 )
=-31.328/317.5835
=-9.86 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Akebia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=46.316/( (321.587+313.58)/ 2 )
=46.316/317.5835
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Akebia Therapeutics Total Assets Related Terms

Akebia Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Total Assets Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 468.47 336.12 221.64 210.74 321.59

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 286.92 299.63 310.26 321.59 313.58
STU:AX9
50GF Score
Akebia Therapeutics Inc STU:AX9
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Akebia Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=27.849+293.738
=321.6

Akebia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=23.679+289.9
=313.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €313.6 Mil mean?
Akebia Therapeutics (STU:AX9) has a Total Assets of €313.6 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Total Assets too high?
Akebia Therapeutics' current Total Assets is €313.6 Mil. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Total Assets compare to TKNO and ORGO?
Akebia Therapeutics' Total Assets of €313.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Total Assets is €313.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.15, compared to a current price of €0.98 — trading 15.2% below its estimated fair value. The current Total Assets is €313.6 Mil. Akebia Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Total Assets is €313.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.98 is trading 15.2% below its estimated GF Value™ of €1.15. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AX9:

  • Total Assets: €313.6 Mil
  • GF Value™: €1.15 vs. price of €0.98 (15.2% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score

Get the complete analysis for STU:AX9

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price
€1.15
GF Value